KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaborative Agreement Revenue BreakdownCollaborative Agreement Revenue Breakdown AnnualCommercial Revenue By CategoryCommercial Revenue By Category AnnualContractual Obligations AnnualContractual Obligations TotalCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Income TaxNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownRaw Materials By SegmentR&D Revenue By CategoryR&D Revenue By Category AnnualR&D Revenue By Category (Deprecated)Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Gross Profit (2018 - 2025)

Historic Gross Profit for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q3 2025 value amounting to $154.4 million.

  • Ionis Pharmaceuticals' Gross Profit rose 1630.07% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $781.1 million, marking a year-over-year decrease of 144.99%. This contributed to the annual value of $693.9 million for FY2024, which is 1086.57% down from last year.
  • Ionis Pharmaceuticals' Gross Profit amounted to $154.4 million in Q3 2025, which was up 1630.07% from $273.8 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Gross Profit high stood at $437.8 million for Q4 2021, and its period low was $109.0 million during Q1 2021.
  • In the last 5 years, Ionis Pharmaceuticals' Gross Profit had a median value of $142.0 million in 2023 and averaged $179.1 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Gross Profit surged by 112939.53% in 2021 and then plummeted by 6614.65% in 2022.
  • Ionis Pharmaceuticals' Gross Profit (Quarter) stood at $437.8 million in 2021, then plummeted by 66.15% to $148.2 million in 2022, then soared by 116.89% to $321.4 million in 2023, then plummeted by 30.7% to $222.7 million in 2024, then crashed by 30.69% to $154.4 million in 2025.
  • Its Gross Profit stands at $154.4 million for Q3 2025, versus $273.8 million for Q2 2025 and $130.1 million for Q1 2025.